The possibility of lower efficacy and the fear been acquired. In this review, therefore, we will analyse if the recommendations made by Muirhead et al. are of an increased incidence of side effects may explain the reluctance to use recombinant human erythropoi-still valid. etin (r-HuEPO) in patients with impaired renal function who do not yet require dialysis, as well as in Rationale for using r-HuEPO in pre-dialysis transplanted patients with a failing renal allograft.
Introduction
therefore, to try to prevent left ventricular hypertrophy by correcting anaemia before starting renal replacement therapy. Normochromic, normocytic anaemia is a common problem in patients with impaired renal function.
Although the use of recombinant human erythropoie-Factors explaining the reluctance to use r-HuEPO tin (r-HuEPO) for the treatment of renal anaemia in haemodialysis and peritoneal dialysis patients is well Several factors may explain the reluctance to use accepted, its use in patients with impaired renal funcr-HuEPO in pre-dialysis patients and patients with a tion who do not yet require dialysis is more controverfailing renal allograft. First, it was thought that efficacy sial. In 1995, after reviewing >200 papers, Muirhead may be lower due to the presence of uraemic toxins in et al. [1] recommended that '… for pre-dialysis and
patients not yet requiring dialysis. In addition, in failing allograft patients, there is likely little benefit in patients with a failing allograft, the concomitant use prescribing r-HuEPO if the glomerular filtration rate of immunosuppressive drugs could make the bone is less than 15 ml/min, unless there are compelling marrow less responsive, while the inflammatory synclinical indications such as severe angina. The use of drome associated with chronic graft rejection could r-HuEPO at these low levels of renal function may also contribute to erythropoietin resistance. Second, hasten the development of end-stage renal failure …'.
there was a fear of severe side effects in patients who Over the last years, additional clinical information has
do not yet require dialysis, not only in terms of potential aggravation of pre-existing arterial hyperten-Y. Vanrenterghem and J. Vanwalleghem 14 expressed regarding cost-benefit in this group of systemic hypertension played an important role in the pathogenesis of this accelerated glomerular injury was patients.
Over the last few years, several studies have been substantiated further by the study of Reudin et al. [12] , who showed that control of systemic hypertenpublished that have critically analysed most of the above-mentioned concerns. For the pre-dialysis sion could completely prevent the negative effect of correction of anaemia seen in the study of Garcia et al. patients, several prospective controlled trials are available, the three most important being a US study [3] , [11] . Based on an analysis of the slopes of the 1/Scr curve, in neither the US multicentre study [3] nor the an Austrian study [4] and a study published by Roth et al. in 1994 [5] . For renal transplant patients, the Austrian multicentre study [4] could a worsening of residual renal function be demonstrated. In the more information is more anecdotal, and no prospective controlled studies are available.
recent placebo-controlled study by Roth et al. [5] , residual renal function was measured by [125I ]iodothalaAs far as efficacy is concerned, the available data indicate that r-HuEPO is certainly as effective in this mate clearance and followed over a period of 1 year.
Again, no difference between the r-HuEPO-treated and patient group as it is in dialysis patients. The maintenance doses needed to control anaemia are either the control groups could be seen.
Data for patients with a renal allograft are much comparable with, or lower than, those for dialysis patients. As shown in the Austrian study [4] , subcuta-more anecdotal, and no controlled trial is available at the present time. Again, however, data demonstrating neous administration once a week is very effective and is preferable from a practical viewpoint. Also, in renal that treatment with r-HuEPO worsens the residual graft function are lacking. transplant patients in general, greater doses are not needed [6] [7] [8] [9] , although in some patients resistance that
Studies on the socioeconomic consequences and the cost-benefit ratio, as have been done for haemodialysis is probably related to the inflammatory syndrome of chronic rejection can be seen [10] .
patients treated with r-HuEPO, are not yet available for pre-dialysis patients. However, all studies have We can therefore conclude that the concern about lower efficacy of r-HuEPO in pre-dialysis patients and found a significant improvement in clinical condition and quality of life, with an increase in exercise tolerance in patients with a renal allograft is not substantiated. However, it must be noted that at least in some and work capacity. Studies should also address the question of whether the better overall well-being that transplanted patients the presence of a chronically rejecting graft may induce some degree of erythropoi-results from correcting anaemia may result in postponing the start of renal replacement therapy in some etin resistance.
The fear of severe hypertension when giving patients. r-HuEPO to non-dialysed patients is based mainly on the outcomes seen in the first clinical trials in dialysed
The use of r-HuEPO and renal transplantation patients, in which hypertension was one of the most frequent adverse effects. More recently, hypertension is seen less frequently, mainly thanks to less aggressive Soon after the introduction of r-HuEPO into clinical practice, there were suggestions that the higher haemadosage schedules. Using these lower starting dosages in pre-dialysis patients, severe hypertension is seen tocrits at the time of transplantation could predispose subsequent renal transplants to graft thrombosis [13] only rarely after starting r-HuEPO therapy. In the Austrian study, no significant alterations in either and delayed graft function [14] . More recent studies, however, were not able to substantiate these concerns systolic or diastolic blood pressure were seen after starting r-HuEPO treatment [4] . Likewise, in most [15] . According to the data of the Collaborative Transplant Study (CTS ), patients treated with other trials, severe hypertension is not a problem if a rapid correction of anaemia is avoided. In many r-HuEPO before transplantation are doing at least as well as those not treated with r-HuEPO while on patients, however, there is an increased need for antihypertensive drugs. The same holds true for trans-dialysis (G. Opelz, personal communication) .
It is difficult to predict whether the more widespread planted patients with impaired graft function where an increase in anti-hypertensive treatment is quite often use of r-HuEPO will also diminish the percentage of panel reactive HLA antibodies in highly sensitized needed [6 ] .
The most important concern with using r-HuEPO dialysis patients awaiting a renal allograft. Only a few studies have addressed this problem, and the results in pre-dialysis patients was the possibility of worsening of the residual renal function. This concern was based are conflicting [15] . When transfusions stop, some patients also stop making antibodies, while others on the experimental findings in 5/6 nephrectomized rats in which correction of anaemia resulted in an show persistently high panel reactivity. The ideal solution may, of course, be to avoid blood transfusions accelerated deterioration of renal function [11] . While anaemia appeared to have a protective effect on completely at the outset. That this approach, which has become more and more popular over recent years, glomerular injury, rats treated with r-HuEPO had a significantly greater number of sclerosed glomeruli is indeed the best as far as graft outcome is concerned has been challenged once more by the publication of 4 weeks after ablation. The more severe systemic and glomerular hypertension, however, was the most the CTS prospective blood transfusion trial. This showed a significantly better graft survival in patients probable explanation for this accelerated injury. That
